The US Food and Drug Administration (FDA) approved Paxlovid™ (nirmatrelvir tablets and ritonavir tablets; Pfizer) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease, including hospitalization or death, the agency announced on May 25, 2023. Paxlovid is the first oral antiviral […]